DK1200580T3 - Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation - Google Patents

Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation

Info

Publication number: DK1200580T3
Authority: DK; Denmark
Prior art keywords: modulation; mediated immune; immune stimulation; positional modification; oligonucleotide cpg
Prior art date: 1999-08-13

Application number

DK00955527T

Other languages

Danish (da)

English (en)

Inventor

Sudhir Agrawal

Original Assignee

Hybridon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-13

Filing date

2000-08-14

Publication date

2005-04-11

2000-08-14 Application filed by Hybridon Inc filed Critical Hybridon Inc

2005-04-11 Application granted granted Critical

2005-04-11 Publication of DK1200580T3 publication Critical patent/DK1200580T3/da

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 2
230000001404 mediated effect Effects 0.000 title 1
230000004048 modification Effects 0.000 title 1
238000012986 modification Methods 0.000 title 1
230000000638 stimulation Effects 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000000692 anti-sense effect Effects 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

DK00955527T 1999-08-13 2000-08-14 Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation DK1200580T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US14879899P	1999-08-13	1999-08-13
PCT/US2000/022284 WO2001012804A2 (fr)	1999-08-13	2000-08-14	Modulation de la stimulation immunitaire induite par les oligonucleotides cpg par modification de la position des nucleosides
EP00955527A EP1200580B1 (fr)	1999-08-13	2000-08-14	Modulation de la stimulation immunitaire induite par les oligonucleotides cpg par modification de la position des nucleosides

Publications (1)

Publication Number	Publication Date
DK1200580T3 true DK1200580T3 (da)	2005-04-11

Family

ID=22527436

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00955527T DK1200580T3 (da)	1999-08-13	2000-08-14	Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation

Country Status (13)

Country	Link
US (1)	US6476000B1 (fr)
EP (2)	EP1200580B1 (fr)
JP (2)	JP5268214B2 (fr)
KR (1)	KR100651294B1 (fr)
AT (1)	ATE286534T1 (fr)
AU (2)	AU783745B2 (fr)
CA (2)	CA2381993A1 (fr)
DE (1)	DE60017259T2 (fr)
DK (1)	DK1200580T3 (fr)
ES (1)	ES2233426T3 (fr)
MX (1)	MXPA02001610A (fr)
PT (1)	PT1200580E (fr)
WO (1)	WO2001012804A2 (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6558951B1 (en) *	1999-02-11	2003-05-06	3M Innovative Properties Company	Maturation of dendritic cells with immune response modifying compounds
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
DE60131430T2 (de)	2000-01-14	2008-10-16	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
JP2003531915A (ja) *	2000-05-01	2003-10-28	ハイブリドン・インコーポレイテッド	ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
AU2006216669A1 (en) *	2000-12-08	2006-08-31	3M Innovative Properties Company	Compositions and methods for targeted delivery of immune response modifiers
US7105495B2 (en)	2001-04-30	2006-09-12	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7176296B2 (en)	2001-04-30	2007-02-13	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US8114418B2 (en)	2001-06-21	2012-02-14	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—IV
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
WO2003014316A2 (fr) *	2001-08-07	2003-02-20	Dynavax Technologies Corporation	Compositions immunomodulatrices, preparations, et leurs procedes d'utilisation
AU2002361468A1 (en)	2001-08-14	2003-03-18	The Government Of The United States Of America As Represented By The Secretary Of Health And Human S	Method for rapid generation of mature dendritic cells
US7276489B2 (en)	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US20040014779A1 (en) *	2001-11-16	2004-01-22	3M Innovative Properties Company	Methods and compositions related to IRM compounds and toll-like recptor pathways
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
CA2365732A1 (fr) *	2001-12-20	2003-06-20	Ibm Canada Limited-Ibm Canada Limitee	Etalonnages
JP2005526497A (ja)	2002-02-04	2005-09-08	ビオミラ，インコーポレーテッド	免疫刺激性、共有結合性脂質化オリゴヌクレオチド
CA2475595C (fr) *	2002-02-22	2012-07-10	3M Innovative Properties Company	Procede visant a reduire et a traiter l'immunodepression induite par uv-b
CA2388049A1 (fr)	2002-05-30	2003-11-30	Immunotech S.A.	Oligonucleotides immunostimulateurs et utilisations connexes
ATE488246T1 (de)	2002-08-15	2010-12-15	3M Innovative Properties Co	Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
WO2004053057A2 (fr) *	2002-12-11	2004-06-24	3M Innovative Properties Company	Systemes d'expression genetique et lignees cellulaires de recombinaison
WO2004053104A2 (fr) *	2002-12-11	2004-06-24	Coley Pharmaceutical Group, Inc.	Acides nucleiques 5'cpg et leurs methodes d'utilisation
WO2004053452A2 (fr) *	2002-12-11	2004-06-24	3M Innovative Properties Company	Analyses relatives a l'activite du recepteur de type toll
ES2381309T3 (es)	2002-12-23	2012-05-25	Dynavax Technologies Corporation	Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
JP2006512391A (ja) *	2002-12-30	2006-04-13	スリーエムイノベイティブプロパティズカンパニー	組み合わせ免疫賦活薬
KR101123489B1 (ko)	2003-01-16	2012-03-28	이데라 파마슈티칼즈, 인코포레이티드	개질된 면역자극성 디뉴클레오티드를 이용한 올리고뉴클레오티드-기재 화합물의 면역자극 특성의 조절
US7354907B2 (en) *	2003-02-07	2008-04-08	Idera Pharmaceuticals, Inc.	Short immunomodulatory oligonucleotides
JP2006517974A (ja) *	2003-02-13	2006-08-03	スリーエムイノベイティブプロパティズカンパニー	Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
DE602004030541D1 (de)	2003-02-20	2011-01-27	Univ Connecticut Health Ct	Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
JP2006519020A (ja) *	2003-02-27	2006-08-24	スリーエムイノベイティブプロパティズカンパニー	Ｔｌｒ介在生物活性の選択的調節
KR100681470B1 (ko) *	2003-03-03	2007-02-12	연세대학교 산학협력단	면역반응 증진용 올리고뉴크레오타이드
WO2004078138A2 (fr)	2003-03-04	2004-09-16	3M Innovative Properties Company	Traitement prophylactique de la neoplasie epidermique induite par les uv
EP1603476A4 (fr)	2003-03-13	2010-01-13	3M Innovative Properties Co	Procede d'elimination d'un tatouage
NZ567227A (en) *	2003-03-13	2010-01-29	3M Innovative Properties Co	Methods of improving skin quality through topical application of an immune response modifier such as imiquimod
US20040192585A1 (en)	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
WO2004108072A2 (fr) *	2003-04-10	2004-12-16	3M Innovative Properties Company	Distribution de composes modifiant une reponse immunitaire au moyen de materiaux de support particulaires contenant du metal
CA2526212C (fr)	2003-05-16	2013-08-27	Hybridon, Inc.	Traitement synergique du cancer utilisant des immunomeres en association a des agents chimiotherapeutiques
MXPA06000619A (es)	2003-07-15	2006-04-11	Hybridon Inc	Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
AU2004261987A1 (en) *	2003-07-31	2005-02-10	3M Innovative Properties Company	Compositions for encapsulation and controlled release
JP2007501252A (ja) *	2003-08-05	2007-01-25	スリーエムイノベイティブプロパティズカンパニー	免疫応答調整剤を含有する製剤
AR045261A1 (es)	2003-08-12	2005-10-19	3M Innovative Properties Co	Compuestos que contienen imidazo quinolina o imidazo piridina sustituidos; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos inmunomoduladores
JP2007503268A (ja)	2003-08-25	2007-02-22	スリーエムイノベイティブプロパティズカンパニー	免疫応答修飾化合物の送達
EP1660122A4 (fr) *	2003-08-25	2007-10-24	3M Innovative Properties Co	Combinaisons et traitements immunostimulatoires
ES2406730T3 (es)	2003-08-27	2013-06-07	3M Innovative Properties Company	Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
EP1663222A4 (fr) *	2003-09-02	2008-05-21	3M Innovative Properties Co	Methodes associees au traitement de pathologies des muqueuses
AU2004270201A1 (en) *	2003-09-05	2005-03-17	3M Innovative Properties Company	Treatment for CD5+ B cell lymphoma
AU2004275876B2 (en)	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
AR046046A1 (es)	2003-10-03	2005-11-23	3M Innovative Properties Co	Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US7544697B2 (en)	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
SG122973A1 (en)	2003-10-30	2006-06-29	Coley Pharm Gmbh	C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050096259A1 (en) *	2003-10-31	2005-05-05	3M Innovative Properties Company	Neutrophil activation by immune response modifier compounds
US7897767B2 (en)	2003-11-14	2011-03-01	3M Innovative Properties Company	Oxime substituted imidazoquinolines
CA2545825A1 (fr)	2003-11-14	2005-06-02	3M Innovative Properties Company	Composes d'un anneau d'imidazo substitue par hydroxylamine
MXPA06005910A (es)	2003-11-25	2006-08-23	3M Innovative Properties Co	Sistemas de anillo imidazo sustituido y metodos.
EP1689361A4 (fr) *	2003-12-02	2009-06-17	3M Innovative Properties Co	Combinaisons therapeutiques et methodes faisant appel a des composes irm
US20050226878A1 (en) *	2003-12-02	2005-10-13	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
KR101138131B1 (ko)	2003-12-08	2012-04-23	이데라 파마슈티칼즈, 인코포레이티드	작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절
EP1701955A1 (fr)	2003-12-29	2006-09-20	3M Innovative Properties Company	Imidazoquinolines a substitution arylalcenyle et arylalkynyle
WO2005067500A2 (fr) *	2003-12-30	2005-07-28	3M Innovative Properties Company	Amelioration de la reponse immunitaire
WO2005066169A2 (fr)	2003-12-30	2005-07-21	3M Innovative Properties Company	Sulfonamides d'imidazoquinolinyle, d'imidazopyridinyle et d'imidazonaphtyridinyle
CA2559863A1 (fr)	2004-03-24	2005-10-13	3M Innovative Properties Company	Imidazopyridines, imidazoquinolines, et imidazonaphthyridines a substitution amide
JP2008505857A (ja) *	2004-04-28	2008-02-28	スリーエムイノベイティブプロパティズカンパニー	粘膜ワクチン接種のための組成物および方法
US20050267145A1 (en) *	2004-05-28	2005-12-01	Merrill Bryon A	Treatment for lung cancer
AU2005294805B2 (en)	2004-05-28	2012-02-16	Oryxe	A mixture for transdermal delivery of low and high molecular weight compounds
CA2567789A1 (fr) *	2004-06-08	2006-08-03	Coley Pharmaceutical Gmbh	Oligonucleotide abasique utilise en tant que plate-forme support pour un antigene ainsi qu'un agoniste et un antagoniste immunostimulatoire
WO2005123080A2 (fr)	2004-06-15	2005-12-29	3M Innovative Properties Company	Imidazoquinolines et imidazonaphthyridines substituees par un heterocyclyle contenant un azote
US7897609B2 (en)	2004-06-18	2011-03-01	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
US8026366B2 (en)	2004-06-18	2011-09-27	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (fr)	2004-06-18	2006-06-22	3M Innovative Properties Company	Composes a noyau imidazo a substitutif d'isoxazole, de dihydroisoxazole et d'oxadiazole
EP1786450A4 (fr) *	2004-08-27	2009-11-11	3M Innovative Properties Co	Compositions immunostimulatrices contre le vih
WO2006042254A2 (fr) *	2004-10-08	2006-04-20	3M Innovative Properties Company	Adjuvant pour vaccin a adn
JP5543068B2 (ja)	2004-12-30	2014-07-09	スリーエムイノベイティブプロパティズカンパニー	キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
PT1830876E (pt)	2004-12-30	2015-07-13	Meda Ab	Utilização de imiquimod para o tratamento de metástases cutâneas derivadas de um tumor cancerígeno da mama
ES2392648T3 (es)	2004-12-30	2012-12-12	3M Innovative Properties Company	Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
CA2597092A1 (fr)	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Formulations des gel aqueux contenant des modificateurs de reponse immunitaire
CA2597587A1 (fr)	2005-02-11	2006-08-17	Coley Pharmaceutical Group, Inc.	Composes cycliques imidazo[4,5-c] substitues par oxime et hydroxylamine et procedes associes
US7943610B2 (en)	2005-04-01	2011-05-17	3M Innovative Properties Company	Pyrazolopyridine-1,4-diamines and analogs thereof
JP2008538550A (ja)	2005-04-01	2008-10-30	コーリーファーマシューティカルグループ，インコーポレイテッド	ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物
EP2341059A1 (fr)	2005-10-12	2011-07-06	Idera Pharmaceuticals, Inc.	Composés d'oligonucléotides de régulation immune (IRO) permettant de moduler une réponse immune fondée sur un récepteur de type toll
US7470674B2 (en)	2005-11-07	2008-12-30	Idera Pharmaceuticals, Inc.	Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7776834B2 (en) *	2005-11-07	2010-08-17	Idera Pharmaceuticals, Inc.	Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
AU2005338035B2 (en)	2005-11-07	2012-06-07	Idera Pharmaceuticals, Inc.	Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP1988896A4 (fr)	2006-02-22	2011-07-27	3M Innovative Properties Co	Conjugués du modificateur de réponse immune
WO2008008432A2 (fr)	2006-07-12	2008-01-17	Coley Pharmaceutical Group, Inc.	Composés à cycle [1,2] imidazo [4,5-c] fusionné chiral substitué et procédés correspondants
KR101251707B1 (ko)	2006-09-27	2013-04-11	콜리 파마슈티칼 게엠베하	면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
US20080149123A1 (en)	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
KR20100066512A (ko) *	2007-08-15	2010-06-17	이데라 파마슈티칼즈, 인코포레이티드	톨 유사 수용체 조절자
CN102281880A (zh) *	2008-10-06	2011-12-14	艾德拉药物股份有限公司	类Toll受体抑制剂在高胆固醇血症和高脂血症及相关疾病的预防和治疗中的用途
WO2011005942A2 (fr) *	2009-07-08	2011-01-13	Idera Pharmaceuticals, Inc.	Composés à base d'oligonucléotide en tant qu'inhibiteurs de récepteurs de type toll
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
EP3213770B1 (fr)	2010-11-19	2021-02-24	Idera Pharmaceuticals, Inc.	Composés d'oligonucléotides de régulation immune (iro) permettant de moduler une réponse immune fondée sur un récepteur de type toll
CA2838158C (fr)	2011-06-03	2019-07-16	3M Innovative Properties Company	Lieurs heterobifonctionnels comportant de segments de polyethylene glycol et conjugues modificateurs de reponse immunitaire obtenus a partir de ceux-ci
EP3366311B1 (fr)	2011-06-03	2020-02-26	3M Innovative Properties Co.	Hydrazino-1h-imidazoquinoléine-4-amines et conjugués obtenus à partir de celles-ci
US20130023736A1 (en)	2011-07-21	2013-01-24	Stanley Dale Harpstead	Systems for drug delivery and monitoring
WO2015011254A1 (fr)	2013-07-26	2015-01-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés et compositions pharmaceutiques pour le traitement d'infections bactériennes
WO2016180852A1 (fr)	2015-05-12	2016-11-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés de préparation de cellules t spécifiques de l'antigène à partir d'un échantillon de sang de cordon ombilical
EP3349717A4 (fr)	2015-09-17	2019-04-17	JRX Biotechnology, Inc.	Approches pour améliorer l'hydratation ou l'humidification de la peau
JP6583864B2 (ja) *	2015-09-30	2019-10-09	塩野義製薬株式会社	免疫賦活活性を有する核酸誘導体
US10940201B2 (en)	2015-09-30	2021-03-09	Shionogi & Co., Ltd.	Nucleic acid derivative having immunostimulatory activity
WO2017059280A1 (fr)	2015-10-02	2017-04-06	The University Of North Carolina At Chapel Hill	Nouveaux inhibiteurs de pan-tam et doubles inhibiteurs de mer/axl
JP7200093B2 (ja)	2016-09-15	2023-01-06	アイデラ・ファーマシューティカルズ，インコーポレーテッド	がん治療用ｔｌｒ９アゴニストを用いた免疫調節
SG11201908059YA (en) *	2017-03-29	2019-10-30	Shionogi & Co	Nucleic acid derivative having immunostimulatory activity
EP3759129A1 (fr)	2018-02-28	2021-01-06	Pfizer Inc	Variants d'il-15 et leurs utilisations
PL3797121T3 (pl)	2018-05-23	2024-09-23	Pfizer Inc.	Przeciwciała swoiste dla CD3 i ich zastosowania
EP3796983A2 (fr)	2018-05-23	2021-03-31	Pfizer Inc.	Anticorps spécifiques de gucy2c et leurs utilisations
WO2020128893A1 (fr)	2018-12-21	2020-06-25	Pfizer Inc.	Traitements combinés de cancer comprenant un agoniste de tlr
JP7369297B2 (ja)	2019-12-17	2023-10-25	ファイザー・インク	Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
MX2023000662A (es)	2020-07-17	2023-02-27	Pfizer	Anticuerpos terapeuticos y sus usos.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5149798A (en)	1989-04-06	1992-09-22	Worcester Foundation For Experimental Biology	Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
US6153595A (en) *	1990-08-16	2000-11-28	Isis Pharmaceuticals Inc.	Composition and method for treatment of CMV infections
AU3249793A (en) *	1991-12-24	1993-07-28	Isis Pharmaceuticals, Inc.	Compositions and methods for modulating beta -amyloid
US6235723B1 (en) *	1992-03-16	2001-05-22	Isis Pharmaceuticals , Inc.	Antisense oligonucleotide modulation of human protein kinase C-δ expression
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5591721A (en) *	1994-10-25	1997-01-07	Hybridon, Inc.	Method of down-regulating gene expression
US5968909A (en) *	1995-08-04	1999-10-19	Hybridon, Inc.	Method of modulating gene expression with reduced immunostimulatory response
US5652356A (en) *	1995-08-17	1997-07-29	Hybridon, Inc.	Inverted chimeric and hybrid oligonucleotides
US5856462A (en) *	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
US5886165A (en) *	1996-09-24	1999-03-23	Hybridon, Inc.	Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
EP1007657B1 (fr) *	1997-08-19	2006-02-08	Idera Pharmaceuticals, Inc.	Nouveaux oligonucleotides synthetiques specifiques au vih et leurs procedes d'utilisation
US6228642B1 (en) *	1998-10-05	2001-05-08	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression

2000
- 2000-08-14 JP JP2001517689A patent/JP5268214B2/ja not_active Expired - Fee Related
- 2000-08-14 CA CA002381993A patent/CA2381993A1/fr not_active Abandoned
- 2000-08-14 AT AT00955527T patent/ATE286534T1/de active
- 2000-08-14 PT PT00955527T patent/PT1200580E/pt unknown
- 2000-08-14 WO PCT/US2000/022284 patent/WO2001012804A2/fr not_active Ceased
- 2000-08-14 EP EP00955527A patent/EP1200580B1/fr not_active Expired - Lifetime
- 2000-08-14 AU AU67720/00A patent/AU783745B2/en not_active Ceased
- 2000-08-14 KR KR1020027001695A patent/KR100651294B1/ko not_active Expired - Fee Related
- 2000-08-14 CA CA2784789A patent/CA2784789A1/fr not_active Abandoned
- 2000-08-14 DE DE60017259T patent/DE60017259T2/de not_active Expired - Lifetime
- 2000-08-14 ES ES00955527T patent/ES2233426T3/es not_active Expired - Lifetime
- 2000-08-14 MX MXPA02001610A patent/MXPA02001610A/es active IP Right Grant
- 2000-08-14 EP EP10010051A patent/EP2314693A3/fr not_active Withdrawn
- 2000-08-14 US US09/639,250 patent/US6476000B1/en not_active Expired - Lifetime
- 2000-08-14 DK DK00955527T patent/DK1200580T3/da active
2005
- 2005-12-12 AU AU2005242217A patent/AU2005242217A1/en not_active Withdrawn
2010
- 2010-09-22 JP JP2010212544A patent/JP2011019527A/ja active Pending

Also Published As

Publication number	Publication date
AU6772000A (en)	2001-03-13
WO2001012804A3 (fr)	2001-09-07
DE60017259T2 (de)	2005-12-08
US6476000B1 (en)	2002-11-05
EP2314693A2 (fr)	2011-04-27
EP1200580B1 (fr)	2005-01-05
ES2233426T3 (es)	2005-06-16
KR100651294B1 (ko)	2006-11-28
MXPA02001610A (es)	2003-07-21
CA2381993A1 (fr)	2001-02-22
EP2314693A3 (fr)	2012-11-28
WO2001012804A2 (fr)	2001-02-22
DE60017259D1 (de)	2005-02-10
JP2011019527A (ja)	2011-02-03
JP5268214B2 (ja)	2013-08-21
PT1200580E (pt)	2005-03-31
AU783745B2 (en)	2005-12-01
ATE286534T1 (de)	2005-01-15
CA2784789A1 (fr)	2001-02-22
AU2005242217A1 (en)	2006-01-12
KR20020059586A (ko)	2002-07-13
EP1200580A2 (fr)	2002-05-02
JP2003526628A (ja)	2003-09-09

Publication	Publication Date	Title
DK1200580T3 (da)	2005-04-11	Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
DK1278761T3 (da)	2005-08-08	Modulering af oligonukleotid CpG-medieret immunstimulering ved hjælp af positionsmodificering af nukleosider
WO2001055370A3 (fr)	2002-01-17	MODULATION DE LA STIMULATION IMMUNE INDUITE PAR CpG OLIGONUCLEOTIDIQUE, PAR MODIFICATION DE LA POSITION DES NUCLEOCIDES
DK1117672T3 (da)	2009-12-07	Antisense-modulation af survivin-ekpression
DK1250455T3 (da)	2008-08-18	Antisense-inhibering af PTP1B-ekspression
WO2002036743A3 (fr)	2003-01-16	Modulation antisens de l'expression de calreticuline
ATE496127T1 (de)	2011-02-15	Antisense-modulation der clusterinexpression
EP1131465A4 (fr)	2004-05-26	Modulation antisens de l'expression de l'interleukine 15
EP1417351A4 (fr)	2005-06-01	Modulation antisens de l'expression de l'apolipoproteine (a)
EP2199299A3 (fr)	2010-10-20	Modulation par antisens de l'expression de survivine
WO2003046132A3 (fr)	2003-08-07	Modulation antisens de l'expression du myd88
WO2003053341A3 (fr)	2005-05-26	Modulation antisens de l'expression de ship-1
WO2001083513A3 (fr)	2002-05-23	Modulation antisens de l'inhibiteur de l'expression de la fixation 1 a l'adn
WO2002095053A3 (fr)	2003-05-01	Modulation antisens de l'expression des src-c
EP1165145A4 (fr)	2003-03-05	Regulation antisens d'expression de mdmx
WO2003057847A3 (fr)	2003-12-11	Procedes et substances de modulation de l'enac-beta
WO2003044163A3 (fr)	2004-04-15	Modulation antisens de l'expression d'un recepteur 4 de type toll
WO2003031576A3 (fr)	2003-09-12	Modulation antisens de l'expression de l'inhibiteur kappa b kinase-gamma
WO2003053342A3 (fr)	2004-03-04	Modulation antisens de l'expression du cd81
WO2002055535A3 (fr)	2002-10-31	Modulation antisens de l'expression de la cytohesine-1
WO2002097108A3 (fr)	2004-06-03	Modulation antisens de l'expression de la phosphatase 5 double specificite
WO2003030617A3 (fr)	2003-12-04	Modulation antisens de l'expression de la creb
EP1496121A3 (fr)	2005-02-09	Modulation de la stimulation immunitaire d'oligonucléotides ayant des CpG par modification positionelle de nucléotides
WO2003038050A3 (fr)	2004-04-01	Modulation antisens de l'expression du groupe v des phospholipases a2
WO2003050246A3 (fr)	2005-02-17	Modulation antisens de l'expression de nod1